51 studies found for:    vismodegib
Show Display Options
Rank Status Study
1 Active, not recruiting Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue light
2 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
3 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
4 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
5 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
6 Not yet recruiting A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Condition: Prostate Cancer
Intervention: Drug: Vismodegib
7 Recruiting Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Condition: Pontine Glioma
Intervention: Drug: Vismodegib
8 Unknown  Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
9 Active, not recruiting
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib 150 mg
10 Active, not recruiting Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Diffuse Large B-cell Lymphoma;   "Indolent" Non-hodgkin Lymphoma;   Primary Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Vismodegib
12 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Active, not recruiting Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: vismodegib;   Drug: gemcitabine hydrochloride;   Other: hydrocortisone/placebo
14 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Drug: vismodegib;   Other: pharmacological study
15 Active, not recruiting Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Condition: Basal Cell Carcinomas
Interventions: Drug: Vismodegib;   Drug: Placebo
16 Active, not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Other: diagnostic laboratory biomarker analysis
17 Completed A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Condition: Basal Cell Carcinoma
Intervention: Drug: vismodegib (GDC-0449)
18 Active, not recruiting Cisplatin and Etoposide Phosphate With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: vismodegib;   Drug: cisplatin;   Drug: etoposide phosphate
19 Active, not recruiting Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Conditions: Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: vismodegib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
20 Active, not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: vismodegib;   Other: diagnostic laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years